These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25667992)

  • 1. Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014).
    Chan-Tack KM; Kim C; Moruf A; Birnkrant DB
    Antivir Ther; 2015; 20(5):561-4. PubMed ID: 25667992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.
    Kawai N; Ikematsu H; Iwaki N; Maeda T; Kawashima T; Hirotsu N; Kashiwagi S
    Clin Infect Dis; 2009 Apr; 48(7):996-7. PubMed ID: 19260819
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children.
    Sugaya N; Tamura D; Yamazaki M; Ichikawa M; Kawakami C; Kawaoka Y; Mitamura K
    Clin Infect Dis; 2008 Aug; 47(3):339-45. PubMed ID: 18582202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.
    Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C
    Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
    Dulek DE; Williams JV; Creech CB; Schulert AK; Frangoul HA; Domm J; Denison MR; Chappell JD
    Clin Infect Dis; 2010 Jun; 50(11):1493-6. PubMed ID: 20415572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus.
    Wijaya L; Chua YY; Cui L; Chan K; Tan BH
    Singapore Med J; 2011 Jul; 52(7):481-5. PubMed ID: 21808957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracorporeal membrane oxygenation for severe refractory respiratory failure secondary to 2009 H1N1 influenza A.
    Turner DA; Rehder KJ; Peterson-Carmichael SL; Ozment CP; Al-Hegelan MS; Williford WL; Peters MA; Noble PW; Cheifetz IM
    Respir Care; 2011 Jul; 56(7):941-6. PubMed ID: 21352668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.
    Escuret V; Cornu C; Boutitie F; Enouf V; Mosnier A; Bouscambert-Duchamp M; Gaillard S; Duval X; Blanchon T; Leport C; Gueyffier F; Van Der Werf S; Lina B
    Antiviral Res; 2012 Nov; 96(2):130-7. PubMed ID: 22909899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.
    Gaur AH; Bagga B; Barman S; Hayden R; Lamptey A; Hoffman JM; Bhojwani D; Flynn PM; Tuomanen E; Webby R
    N Engl J Med; 2010 Jan; 362(1):88-9. PubMed ID: 20032317
    [No Abstract]   [Full Text] [Related]  

  • 12. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.
    Sorbello A; Jones SC; Carter W; Struble K; Boucher R; Truffa M; Birnkrant D; Gada N; Camilli S; Chan I; Dallas S; Scales T; Kosko R; Thompson E; Goodman J; Francis H; Dal Pan G
    Clin Infect Dis; 2012 Jul; 55(1):1-7. PubMed ID: 22491501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.
    Hernandez JE; Adiga R; Armstrong R; Bazan J; Bonilla H; Bradley J; Dretler R; Ison MG; Mangino JE; Maroushek S; Shetty AK; Wald A; Ziebold C; Elder J; Hollister AS; Sheridan W;
    Clin Infect Dis; 2011 Mar; 52(6):695-706. PubMed ID: 21367722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons.
    Wkly Epidemiol Rec; 2007 Apr; 82(17):149-50. PubMed ID: 17465078
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
    Heneghan CJ; Onakpoya I; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Mahtani KR; Nunan D; Howick J; Jefferson T
    Health Technol Assess; 2016 May; 20(42):1-242. PubMed ID: 27246259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.
    Dharan NJ; Beekmann SE; Fiore A; Finelli L; Uyeki TM; Polgreen PM; Fry AM
    Antiviral Res; 2010 Nov; 88(2):182-6. PubMed ID: 20739002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
    Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
    Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
    Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
    J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of antiviral agents for the management of severe influenza.
    Smith JR; Ariano RE; Toovey S
    Crit Care Med; 2010 Apr; 38(4 Suppl):e43-51. PubMed ID: 19935416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.